Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Novo Nordisk to invest $506 million in Ireland plant expansion

Published by Global Banking & Finance Review

Posted on March 2, 2026

1 min read

· Last updated: April 2, 2026

Add as preferred source on Google

Novo Nordisk to invest $506 million in Ireland plant expansion

Finance Banking Markets

Global Banking & Finance Awards 2026 — Call for Entries

COPENHAGEN, March 2 (Reuters) - Novo Nordisk said on Monday it will invest 432 million euros ($506.43 million) to expand its manufacturing facility in Athlone, Ireland. “With the investment in the

Novo Nordisk to invest $506 million in Ireland plant expansion

Details of Novo Nordisk's Investment in Ireland

Correction Notice

(Corrects headline to $506 million, not $470 million; corrects text to 432 million euros, not more than 400 million)

Investment Announcement

Expansion Plans

COPENHAGEN, March 2 (Reuters) - Novo Nordisk said on Monday it will invest 432 million euros ($506.3 million) to expand its manufacturing facility in Athlone, Ireland.

Currency Exchange Rate

($1 = 0.8530 euros)

Reporting Credits

(Reporting by Stine Jacobsen, editing by Louise Rasmussen)

Key Takeaways

Investment will expand oral GLP‑1 manufacturing capacity at Athlone site to meet global demand beyond the U.S. (meawards.ie)
Novo Nordisk acquired the Athlone facility from Alkermes in late 2023 (~€85m purchase), and had earlier dropped plans for a larger Dublin plant, refocusing efforts on Monksland expansion (westmeathindependent.ie)
The Wegovy pill launch in January 2026 has been notably successful (over 240,000 U.S. users), underpinning the need for increased production capacity internationally (meawards.ie)

References

Frequently Asked Questions

How much is Novo Nordisk investing in its Ireland plant expansion?

Novo Nordisk is investing 432 million euros ($506.43 million) to expand its manufacturing facility in Athlone, Ireland.

What will the expansion of the Athlone facility focus on?

The expansion will focus on increasing production capacities for oral GLP-1 drugs such as Wegovy and Ozempic.

When will the construction projects for the Athlone plant be completed?

The construction will be finalised gradually from the end of 2027 through 2028.

Why is Novo Nordisk expanding its Athlone facility?

The expansion aims to strengthen Novo Nordisk's ability to meet current and future demand for oral products outside the U.S.

More from Finance

Explore more articles in the Finance category

Fertiliser plant in Russia's Vologda region damaged in Ukrainian drone attack, governor says

Close Brothers will not take legal action against Britain's car finance redress scheme, Sky News reports

Germany's far-right AfD rises to record 28%, INSA poll shows

German government suspects Russia of Signal attack targeting politicians, sources say

Romania finds parts of second drone after overnight Russian attack on Ukraine

China condemns EU's inclusion of Chinese entities in sanctions package against Russia

Russian parliament speaker in North Korea to mark Pyongyang's troop deployment in Ukraine war

Macron reaffirms efforts to reopen Strait of Hormuz, as TotalEnergies warns of energy shortages

France's Macron says EU mutual assistance clause is unambiguous

US to let Venezuela pay Maduro's lawyer in drug trafficking case

Italy votes down equal parental leave while fathers redefine their role online

German auto industry faces even tougher competition as China economy slows

View All Finance Posts

Novo Nordisk to invest $506 million in Ireland plant expansion

Novo Nordisk to invest $506 million in Ireland plant expansion